MAPT and Alzheimer disease: (2017) demonstrated that [18F]GE‐180 permitted detection of decreased cortical and hippocampal neuroinflammation in the APPL/S mouse following treatment with LM11A‐31, a clinical AD treatment which attenuates tau phosphorylation, neurite degeneration and microglial activation.